FHDH-ANRS CO4 Cohort: HCV Incidence in MSM With HIV Declined Following Access to HCV DAA Therapy in France

March 8-11, 2020; Boston, Massachusetts
HCV incidence in MSM with HIV in France declined from 2014 to 2017 following unrestricted access of HCV DAA therapy for persons with HIV.
Format: Microsoft PowerPoint (.ppt)
File Size: 156 KB
Released: March 17, 2020

Acknowledgements

Provided by USF Health, in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Gilead Sciences
ViiV Healthcare

Related Content

Dr Mark Sulkowski and Clinical Care Options (CCO): Treatment of both HIV and HCV should be prioritized for patients that are coinfected with careful consideration of drug-drug interactions.

Mark S. Sulkowski, MD Released: January 19, 2022

Slides from CCO: Discussion of key data and recommendations for choosing ART regimens for older patients with renal impairment or liver disease.

Jonathan Appelbaum, MD, FACP, AAHIVS Jens D. Lundgren, MD, DMSc Released: January 13, 2022

Free slides from CCO featuring data on racial inequities in HIV care in BIPOC communities and strategies to combat racial disparities in HIV

person default Solange L. Baptiste, ScM Rageshri Dhairyawan, MBBS, BSc, FCRP, DipGUM, DipHIV, DFSRH person default Samantha V. Hill, MD, MPH David Malebranche, MD, MPH Released: January 11, 2022

Clinical Care Options (CCO): woman’s perspective on her struggle with HIV stigma and why volunteering to help others with HIV has become her purpose

person default Anonymous Patient Released: January 10, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings